The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Effects of Medical Therapies on Retinopathy Progression in Type 2 Diabetes
Open accessAbstract
BACKGROUND: We investigated whether intensive glycemic control, combination therapy for dyslipidemia, and intensive blood-pressure control would limit the progression of diabetic retinopathy in persons with type 2 diabetes. Previous data suggest that these systemic factors may be important in the development and progression of diabetic retinopathy. METHODS: In a randomized trial, we enrolled 10,251 participants with type 2 diabetes who were at high risk for cardiovascular disease to receive either intensive or standard treatment for glycemia (target glycated hemoglobin level, <6.0% or 7.0 to 7.9%, respectively) and also for dyslipidemia (160 mg daily of fenofibrate plus simvastatin or placebo plus simvastatin) or for systolic blood-pressure control (target, <120 or <140 mm Hg). A subgroup of 2856 participants was evaluated for the effects of these interventions at 4 years on the progression of diabetic retinopathy by 3 or more steps on the Early Treatment Diabetic Retinopathy Study Severity Scale (as assessed from seven-field stereoscopic fundus photographs, with 17 possible steps and a higher number of steps indicating greater severity) or the development of diabetic retinopathy necessitating laser photocoagulation or vitrectomy. RESULTS: At 4 years, the rates of progression of diabetic retinopathy were 7.3% with intensive glycemia treatment, versus 10.4% with standard therapy (adjusted odds ratio, 0.67; 95% confidence interval [CI], 0.51 to 0.87; P=0.003); 6.5% with fenofibrate for intensive dyslipidemia therapy, versus 10.2% with placebo (adjusted odds ratio, 0.60; 95% CI, 0.42 to 0.87; P=0.006); and 10.4% with intensive blood-pressure therapy, versus 8.8% with standard therapy (adjusted odds ratio, 1.23; 95% CI, 0.84 to 1.79; P=0.29). CONCLUSIONS: Intensive glycemic control and intensive combination treatment of dyslipidemia, but not intensive blood-pressure control, reduced the rate of progression of diabetic retinopathy. (Funded by the National Heart, Lung, and Blood Institute and others; ClinicalTrials.gov numbers, NCT00000620 for the ACCORD study and NCT00542178 for the ACCORD Eye study.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary composite major CV outcomes (nonfatal MI, nonfatal stroke or death from CV causes) were not reduced significantly in ACCORD (hazard ratio [HR] 0.90, p=0.16).”
From Targets for Glycemic Control (2018) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In people with type 2 diabetes, an A1C ≤6.5% may be targeted to reduce the risk of CKD [Grade A, Level 1A (23)] and retinopathy [Grade A, Level 1A (21)], if they are assessed to be at low risk of hypoglycemia based on class of antihyperglycemic medication(s) utilized and the person's characteristics [Grade D, Consensus].”
From Targets for Glycemic Control (2018) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The UK Prospective Diabetes Study randomly assigned 4209 patients with newly diagnosed type 2 diabetes to receive conventional (primarily diet) vs intensive (insulin, sulfonylurea, or, if overweight, metformin) treatment, with mean attained HbA1C of 7.9% vs 7.0%, respectively.36,37”
From Diagnosis and Treatment of Type 2 Diabetes in Adults (2025) · cites this paper as [36]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Other options that can stabilize retinopathy include lifestyle intervention or bariatric surgery in persons with T2D or physical activity in persons with T1D.524–527”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [527]
Experimental — accuracy not yet measuredIn the citing paper
“Fenofibrate reduces the progression of diabetic retinopathy.413,414”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [414]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Multiple Imputation for Nonresponse in Surveys
Rubin, D. B. (1987) · Wiley Series in Probability and Statistics · doi:10.1002/9780470316696 · Cited by 20,701
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Self-citationIntensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Self-citationStearne, M. R., Palmer, S. L., Hammersley, M. S., Franklin, S. L., Spivey, R. S., Lévy, J., Tidy, C. R., Bell, N. J., Steemson, J., Barrow, B. A., et al. (1998) · UCL Discovery (University College London) · Cited by 4,803
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762
Gupta, A., & Uribarri, J. (2016) · Hormone Research in Paediatrics · doi:10.1159/000444053 · Cited by 4,023
Effects of intensive blood-pressure control in type 2 diabetes mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001286 · Cited by 3,598
Self-citation
Flagged first, then by citations
Research works printed but not linked: 4
- Davis MD, 1998, Invest Ophthalmol Vis Sci, 39, 233
- Cullen JF, 1964, Trans Ophthalmol Soc U K, 84, 281
- The ACCORD Study Group, 2007, Am J Cardiol, 99, 21i
- Ismail-Beigi F, 2010, Lancet, 375, 26
Cited by
Sorted by citations
Items 201–300 of 1,000
Picconi, F., Parravano, M., Ylli, D., Pasqualetti, P., Coluzzi, S., Giordani, I., Malandrucco, I., Lauro, D., Scarinci, F., Giorno, P., et al. (2017) · Acta Diabetologica · doi:10.1007/s00592-017-0971-4 · Cited by 84
Kanat, M., DeFronzo, R. A., & Abdul‐Ghani, M. A. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i12.1207 · Cited by 87
Ting, D. S. W., Cheung, C. Y.-L., Nguyen, Q., Sabanayagam, C., Lim, G., Lim, Z. W., Tan, G. S. W., Soh, Y. Q., Schmetterer, L. F., Wang, Y. X., et al. (2019) · npj Digital Medicine · doi:10.1038/s41746-019-0097-x · Cited by 85
Diabetic macular ischaemia- a new therapeutic target?
Cheung, C. M. G., Fawzi, A. A., Teo, K. Y. C., Fukuyama, H., Sen, S., Tsai, W.-S., & Sivaprasad, S. (2021) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2021.101033 · Cited by 84
Associations between complications and health‐related quality of life in individuals with diabetes
Venkataraman, K., Wee, H. L., Leow, M. K., Tai, E. S., Lee, J., Lim, S. C., Tavintharan, S., Wong, T. Y., Ma, S., Heng, D., et al. (2012) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2012.04480.x · Cited by 83
Gologorsky, D., Thanos, A., & Vavvas, D. G. (2012) · Mediators of Inflammation · doi:10.1155/2012/629452 · Cited by 84
Diabetic retinopathy and systemic factors
Frank, R. N. (2015) · Middle East African Journal of Ophthalmology · doi:10.4103/0974-9233.154388 · Cited by 81
Screening for Type 2 Diabetes and Dysglycemia
Echouffo-Tcheugui, J. B., Ali, M. K., Griffin, S. J., & Narayan, K. M. V. (2011) · Epidemiologic Reviews · doi:10.1093/epirev/mxq020 · Cited by 87
Dicembrini, I., Nreu, B., Scatena, A., Andreozzi, F., Sesti, G., Mannucci, E., & Monami, M. (2017) · Acta Diabetologica · doi:10.1007/s00592-017-1031-9 · Cited by 83
ω-3 and ω-6 long-chain PUFAs and their enzymatic metabolites in neovascular eye diseases
Gong, Y. Q., Fu, Z., Liegl, R. G.-H., Chen, J., Hellström, A., & Smith, L. E. H. (2017) · American Journal of Clinical Nutrition · doi:10.3945/ajcn.117.153825 · Cited by 79
Corcóstegui, B., Durán, S., González-Albarrán, M. O., Hernández, C., Ruiz‐Moreno, J. M., Salvador, J., Udaondo, P., & Simó, R. (2017) · Journal of Ophthalmology · doi:10.1155/2017/8234186 · Cited by 83
Ciudin, A., Espinosa, A., Simó‐Servat, O., Ruiz, A., Alegret, M., Hernández, C., Boada, M., & Simó, R. (2017) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2017.04.018 · Cited by 78
Li, S., Deng, J., Sun, D., Chen, S., Yao, X., Wang, N., Zhang, J., Gu, Q., Zhang, S., Wang, J., et al. (2022) · Redox Biology · doi:10.1016/j.redox.2022.102530 · Cited by 81
Blood pressure control for diabetic retinopathy
Diana, V., Han, G., Abariga, S. A., Sleilati, G. G., Vedula, S. S., & Hawkins, B. S. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006127.pub3 · Cited by 85
Evidence‐based Danish guidelines for screening of diabetic retinopathy
Grauslund, J., Andersen, N., Andresen, J., Flesner, P., Haamann, P., Heegaard, S., Larsen, M., Laugesen, C. S., Schielke, K. C., Skov, J., et al. (2018) · Acta Ophthalmologica · doi:10.1111/aos.13936 · Cited by 79
Role of Inflammation in Classification of Diabetic Macular Edema by Optical Coherence Tomography
Chung, Y.-R., Kim, Y. H., Ha, S. J., Byeon, H.-E., Cho, C., Kim, J. H., & Lee, K. (2019) · Journal of Diabetes Research · doi:10.1155/2019/8164250 · Cited by 77
New treatments for diabetic retinopathy
Das, A., Stroud, S. R., Mehta, A. M., & Rangasamy, S. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12384 · Cited by 76
Hermans, M. P., Ahn, S. A., & Rousseau, M. F. (2010) · Cardiovascular Diabetology · doi:10.1186/1475-2840-9-88 · Cited by 76
Miranda, S., González‐Rodríguez, Á., García‐Ramírez, M., Revuelta‐Cervantes, J., Hernández, C., Simó, R., & Valverde, Á. M. (2011) · Journal of Cellular Physiology · doi:10.1002/jcp.22970 · Cited by 79
Siwasaranond, N., Nimitphong, H., Manodpitipong, A., Saetung, S., Chirakalwasan, N., Thakkinstian, A., & Reutrakul, S. (2018) · Journal of Diabetes Research · doi:10.1155/2018/9269170 · Cited by 75
Four-Year Incidence of Diabetic Retinopathy in a Spanish Cohort: The MADIABETES Study
Salinero-Fort, M. Á., Andrés-Rebollo, F. J. S., de Burgos‐Lunar, C., Arrieta-Blanco, F. J., Gómez‐Campelo, P., & on behalf of MADIABETES Group (2013) · PLoS ONE · doi:10.1371/journal.pone.0076417 · Cited by 76
Long-term remission of type 2 diabetes in morbidly obese patients after sleeve gastrectomy
Abbatini, F., Capoccia, D., Casella, G., Soricelli, E., Leonetti, F., & Basso, N. (2012) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2012.09.003 · Cited by 74
Moon, J. S., Kang, S., Choi, J. H., Lee, K. A., Moon, J. H., Chon, S., Kim, D. J., Kim, H. J., Seo, J. A., Kim, M. K., et al. (2024) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2024.0249 · Cited by 81
Lian, F., Wu, L., Tian, J., Jin, M., Zhou, S., Zhao, M., Wei, L., Zheng, Y., Wang, Y., Zhang, M., et al. (2015) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2015.01.048 · Cited by 74
Medical management of diabetic retinopathy: fenofibrate and ACCORD Eye studies
Wright, A. D., & Dodson, P. M. (2011) · Eye · doi:10.1038/eye.2011.62 · Cited by 75
Calcium dobesilate for diabetic retinopathy: a systematic review and meta-analysis
Zhang, X., Liu, W., Wu, S., Jin, J., Li, W., & Wang, N. (2014) · Science China Life Sciences · doi:10.1007/s11427-014-4792-1 · Cited by 74
Cost-effectiveness of an electronic medical record based clinical decision support system
Gilmer, T. P., O'Connor, P. J., Sperl‐Hillen, J. M., Rush, W. A., Johnson, P. E., Amundson, G. H., Asche, S. E., & Ekstrom, H. L. (2012) · Health Services Research · doi:10.1111/j.1475-6773.2012.01427.x · Cited by 73
Current and Novel Therapeutic Approaches for Treatment of Diabetic Macular Edema
Chauhan, M. Z., Rather, P. A., Samarah, S. M., Elhusseiny, A. M., & Sallam, A. B. (2022) · Cells · doi:10.3390/cells11121950 · Cited by 75
Hooper, P., Boucher, M. C., Cruess, A. F., Dawson, K. G., Delpero, W., Greve, M. D. J., Kožoušek, V., Lam, W., & Maberley, D. (2012) · Canadian Journal of Ophthalmology · doi:10.1016/j.jcjo.2011.12.025 · Cited by 76
Protective and Antioxidant Effects of PPARα in the Ischemic Retina
Pearsall, E., Ding, L., Wang, Z., Cheng, R., Chen, Q., Moore, R., Takahashi, Y., & Ma, J. (2014) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.13-13127 · Cited by 73
Neurovascular Unit: A New Target for Treating Early Stages of Diabetic Retinopathy
Simó, R., Simó‐Servat, O., Bogdanov, P. M., & Hernández, C. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13081320 · Cited by 77
Diabetic retinopathy: Pathogenic mechanisms and current treatments
Chistiakov, D. A. (2011) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2012.02.025 · Cited by 70
Omega-3 polyunsaturated fatty acids preserve retinal function in type 2 diabetic mice
Sapieha, P. S., Chen, J., Stahl, A., Seaward, M. R., Favazza, T. L., Juan, A. M., Hatton, C., Joyal, J.-S., Krah, N. M., Dennison, R. J., et al. (2012) · Nutrition and Diabetes · doi:10.1038/nutd.2012.10 · Cited by 72
Diabetic Retinopathy: Role of Neurodegeneration and Therapeutic Perspectives
Simó, R., Simó‐Servat, O., Bogdanov, P. M., & Hernández, C. (2022) · Asia-Pacific Journal of Ophthalmology · doi:10.1097/apo.0000000000000510 · Cited by 79
Impact of LDL Cholesterol on Microvascular Versus Macrovascular Disease
Emanuelsson, F., Nordestgaard, B. G., Tybjærg‐Hansen, A., & Benn, M. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.07.037 · Cited by 69
Mancini, G. B. J., Hegele, R. A., & Leiter, L. A. (2018) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.10.019 · Cited by 70
Inhibition of EGF Signaling Protects the Diabetic Retina from Insulin-Induced Vascular Leakage
Sugimoto, M., Cutler, A., Shen, B., Moss, S. E., Iyengar, S. K., Klein, R., Folkman, J., & Anand‐Apte, B. (2013) · American Journal Of Pathology · doi:10.1016/j.ajpath.2013.05.017 · Cited by 70
Sasaki, M., Kawasaki, R., Rogers, S., Man, R. E. K., Itakura, K., Xie, J., Flood, V. M., Tsubota, K., Lamoureux, E. L., & Wang, J. J. (2015) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.15-17485 · Cited by 71
Scott, E. S., Januszewski, A. S., O’Connell, R., Fulcher, G., Scott, R., Kesaniemi, A., Wu, L., Colagiuri, S., Keech, A., & Jenkins, A. J. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa361 · Cited by 70
Ismail‐Beigi, F., Craven, T. E., O’Connor, P. J., Karl, D. M., Calles-Escandón, J., HRAMIAK, I. M., GENUTH, S. M., Cushman, W. C., Gerstein, H. C., Probstfield, J. L., et al. (2011) · Kidney International · doi:10.1038/ki.2011.415 · Cited by 69
Diabetic macular oedema: pathophysiology, management challenges and treatment resistance
Bahrami, B., Zhu, M., Hong, T., & Chang, A. (2016) · Diabetologia · doi:10.1007/s00125-016-3974-8 · Cited by 69
Lipid-lowering in diabetes: An update
Chait, A., Eckel, R. H., Vrablı́k, M., & Zambon, A. (2023) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2023.117313 · Cited by 71
Trudeau, K. M., Roy, S., Guo, W., Hernández, C., Villarroel, M., Simó, R., & Roy, S. (2011) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.11-7282 · Cited by 68
Hemmingsen, B., Lund, S. S., Gluud, C. N., Vaag, A. A., Almdal, T., Hemmingsen, C., & Wetterslev, J. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008143.pub2 · Cited by 69
RetractedRosenson, R. S., Wright, R. S., Farkouh, M. E., & Plutzky, J. (2012) · American Heart Journal · doi:10.1016/j.ahj.2012.06.023 · Cited by 67
Fenofibrate and Diabetic Retinopathy
Knickelbein, J. E., Abbott, A. B., & Chew, E. Y. (2016) · Current Diabetes Reports · doi:10.1007/s11892-016-0786-7 · Cited by 66
Dodo, Y., Suzuma, K., Ishihara, K., Yoshitake, S., Fujimoto, M., Yoshitake, T., Miwa, Y., & Murakami, T. (2017) · Scientific Reports · doi:10.1038/s41598-017-05663-9 · Cited by 68
The High Cost of Diabetes Drugs: Disparate Impact on the Most Vulnerable Patients
Taylor, S. I. (2020) · Diabetes Care · doi:10.2337/dci20-0039 · Cited by 69
Diabetic Retinopathy: Focus on Minority Populations
Barsegian, A., Kotlyar, B., Lee, J., Salifu, M., & McFarlane, S. I. (2017) · International Journal of Clinical Endocrinology and Metabolism · doi:10.17352/ijcem.000027 · Cited by 68
Rosenblatt, A., Udaondo, P., Cunha-Vaz, J., Sivaprasad, S., Bandello, F. M., Lanzetta, P., Kodjikian, L., Goldstein, M., Habot‐Wilner, Z., Loewenstein, A., et al. (2019) · Ophthalmology · doi:10.1016/j.ophtha.2019.10.005 · Cited by 65
Vitamin D Protects against Oxidative Stress and Inflammation in Human Retinal Cells
Fernández‐Robredo, P., González‐Zamora, J., Recalde, S., Bilbao‐Malavé, V., Bezunartea, J., Hernández, M., & García‐Layana, A. (2020) · Antioxidants · doi:10.3390/antiox9090838 · Cited by 65
Diabetic eye disease: A review of screening and management recommendations
Gale, M. J., Scruggs, B. A., & Flaxel, C. J. (2021) · Clinical and Experimental Ophthalmology · doi:10.1111/ceo.13894 · Cited by 65
The role of O ‐GlcNAc signaling in the pathogenesis of diabetic retinopathy
Semba, R. D., Hu, H., Lutty, G. A., Eyk, J. E. V., & Hart, G. W. (2014) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.201300076 · Cited by 70
Serra, A. M., Waddell, J., Manivannan, A., Xu, H., Cotter, M. A., & Forrester, J. V. (2012) · American Journal Of Pathology · doi:10.1016/j.ajpath.2012.04.009 · Cited by 64
Gong, Y. Q., Shao, Z., Fu, Z., Edin, M. L., Sun, Y., Liegl, R. G.-H., Wang, Z., Liu, C., Burnim, S. B., Meng, S. S., et al. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.09.025 · Cited by 63
Emerging insights into the relationship between hyperlipidemia and the risk of diabetic retinopathy
Chou, Y., Ma, J., Su, X., & Zhong, Y. (2020) · Lipids in Health and Disease · doi:10.1186/s12944-020-01415-3 · Cited by 63
A review of therapies for diabetic macular oedema and rationale for combination therapy
Amoaku, W. M. K., Saker, S., & Stewart, E. A. (2015) · Eye · doi:10.1038/eye.2015.110 · Cited by 63
Rodríguez‐Poncelas, A., Miravet-Jiménez, S., Casellas, A., Barrot, J., Franch‐Nadal, J., López‐Simarro, F., Mata‐Cases, M., & Mundet, X. (2015) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2015-306683 · Cited by 66
Diabetic Retinopathy: Battling the Global Epidemic
Das, A. (2016) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.16-21031 · Cited by 65
Waldman, B., Ansquer, J.-C., SULLIVAN, D. R., Jenkins, A. J., McGill, N. W., Buizen, L., Davis, T. M. E., Best, J. D., Li, L., Feher, M. D., et al. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30029-9 · Cited by 63
Diabetic retinopathy: research to clinical practice
Shah, A. R., & Gardner, T. W. (2017) · Clinical Diabetes and Endocrinology · doi:10.1186/s40842-017-0047-y · Cited by 63
Kawasaki, R., Konta, T., & Nishida, K. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13372 · Cited by 62
The Diabetic Retinopathy “Pandemic” and Evolving Global Strategies: The 2023 Friedenwald Lecture
Wong, T. Y., & Tan, T. (2023) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.64.15.47 · Cited by 61
Candidate gene studies of diabetic retinopathy in human
Priščáková, P., Minárik, G., & Repiská, V. (2016) · Molecular Biology Reports · doi:10.1007/s11033-016-4075-y · Cited by 61
CHANGES IN DIABETIC RETINOPATHY SEVERITY WHEN TREATING DIABETIC MACULAR EDEMA WITH RANIBIZUMAB
Bressler, S. B., Odia, I., Glassman, A. R., Danis, R. P., Grover, S., Hampton, G. R., Jampol, L. M., Maguire, M. G., & Melia, M. (2018) · Retina · doi:10.1097/iae.0000000000002302 · Cited by 61
Plasma level of miR-93 is associated with higher risk to develop type 2 diabetic retinopathy
Zou, H., Wang, Y., Gang, Q., Zhang, Y., & Sun, Y. (2017) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-017-3638-5 · Cited by 60
Management of diabetic macular edema in Japan: a review and expert opinion
Terasaki, H., Ogura, Y., Kitano, S., Sakamoto, T., Murata, T., Hirakata, A., & Ishibashi, T. (2017) · Japanese Journal of Ophthalmology · doi:10.1007/s10384-017-0537-6 · Cited by 61
A Review on Diabetic Retinopathy
Kour, V., Swain, J., Singh, J., Singh, H., & Kour, H. (2023) · Current Diabetes Reviews · doi:10.2174/0115733998253672231011161400 · Cited by 61
Chung, Y.-R., Choi, J. A., Koh, J., & Yoon, Y. H. (2017) · Journal of Diabetes Research · doi:10.1155/2017/1763292 · Cited by 58
Silva, M., Peng, T., Zhao, X., Li, S., Farhan, M., & Zheng, W. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.04.007 · Cited by 58
Mounirou, B. A. M., Adam, N. D., Yakoura, A. H., Aminou, M. S. M., Liu, Y., & Tan, L. (2022) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_480_21 · Cited by 57
Usui, Y., Westenskow, P. D., Murinello, S., Dorrell, M. I., Scheppke, L., Bucher, F., Sakimoto, S., Paris, L. P., Aguilar, E., & Friedlander, M. (2015) · Annual Review of Vision Science · doi:10.1146/annurev-vision-082114-035439 · Cited by 59
Shurter, A., Genter, P. M., Ouyang, D., & Ipp, E. (2013) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2013.03.018 · Cited by 57
Soran, H., Schofield, J. D., Adam, S., & Durrington, P. N. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000318 · Cited by 49
Optical coherence tomography in the management of diabetic macular oedema
Szeto, S., Lai, T. Y. Y., Vujosevic, S., Sun, J. K., Sadda, S. R., Tan, G. S. W., Sivaprasad, S., Wong, T. Y., & Cheung, C. Y.-L. (2023) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2023.101220 · Cited by 56
Clinical Implications of the ACCORD Trial
GENUTH, S. M., & Ismail‐Beigi, F. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1679 · Cited by 57
Effect of systemic medications on onset and progression of diabetic retinopathy
Silva, P. S., Cavallerano, J. D., Sun, J. K., Aiello, L. M., & Aiello, L. P. (2010) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.122 · Cited by 57
Epidemiology of Micro- and Macrovascular Complications of Type 2 Diabetes in Korea
Kim, J. H., Kim, D. J., Jang, H. C., & Choi, S. H. (2011) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2011.35.6.571 · Cited by 57
Dysglycaemia, vasculopenia, and the chronic consequences of diabetes
Gerstein, H. C., & Werstuck, G. H. (2013) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70025-1 · Cited by 58
McCann, P., Hogg, R. E., Fallis, R., & Azuara‐Blanco, A. (2016) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.15-18595 · Cited by 57
Liew, G., Wong, V. W., & Ho, I. (2017) · Ophthalmic Epidemiology · doi:10.1080/09286586.2016.1259638 · Cited by 57
PPAR-α agonists are still on the rise: an update on clinical and experimental findings
Ferri, N., Corsini, A., Sirtori, C. R., & Ruscica, M. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1312339 · Cited by 59
The Role of Biofactors in Diabetic Microvascular Complications
Ziegler, D., Porta, M., Παπάνας, Ν., Moța, M., Jermendy, G., Beltramo, E., Mazzeo, A., Caccioppo, A., Striglia, E., Serhiyenko, V. A., et al. (2021) · Current Diabetes Reviews · doi:10.2174/1871527320666210825112240 · Cited by 58
Effects of Medical Therapies on Retinopathy Progression in Type 2 Diabetes
VANDER, J. F. (2011) · Yearbook of Ophthalmology · doi:10.1016/j.yoph.2010.12.007 · Cited by 55
Curovic, V. R., Suvitaival, T., Mattila, I. M., Ahonen, L. L., Trôst, K., Theilade, S., Hansen, T. W., Legido‐Quigley, C., & Rossing, P. R. (2020) · Diabetes · doi:10.2337/db20-0104 · Cited by 55
Koh, K. K., Quon, M. J., Shin, K.-C., Lim, S., Lee, Y., Sakuma, I., Lee, K., Han, S. H., & Shin, E. K. (2012) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.11.018 · Cited by 61
Diabetes mellitus type 2 in adults
Dedov, I. I., Shestakova, M. V., Mayorov, A. Y., Шамхалова, М. Ш., Sukhareva, O. Y., Galstyan, G. R., Tokmakova, A. Y., Nikonova, T. V., Surkova, E. V., Кононенко, И. В., et al. (2020) · Diabetes Mellitus · doi:10.14341/dm12507 · Cited by 60
Wang, N., Zhang, C., Xu, Y., Tan, H., Chen, H., & Feng, Y. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.62868 · Cited by 54
Dominguez, J. M., Hu, P., Caballero, S., Moldovan, L., Verma, A., Oudit, G. Y., Li, Q., & Grant, M. B. (2016) · American Journal Of Pathology · doi:10.1016/j.ajpath.2016.01.023 · Cited by 56
Glucose Control and Vascular Outcomes in Type 2 Diabetes: Is the Picture Clear?
Giorgino, F., Home, P., & Tuomilehto, J. O. (2016) · Diabetes Care · doi:10.2337/dcs15-3023 · Cited by 55
Benefits and risks of the treatment with fibrates––a comprehensive summary
Okopień, B., Bułdak, Ł., & Bołdys, A. (2018) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2018.1537780 · Cited by 55
Du, J., Wang, Y., Tu, Y., Guo, Y., Sun, X., Xu, X., Liu, X., Wang, L., Qin, X., Zhu, M., et al. (2020) · Experimental Eye Research · doi:10.1016/j.exer.2020.108065 · Cited by 54
Factors Associated with Diabetic Retinopathy in Chinese Patients with Type 2 Diabetes Mellitus
He, B., Wei, L., Gu, Y., Han, J., Li, M., Liu, Y., Bao, Y., & Jia, W. (2012) · International Journal of Endocrinology · doi:10.1155/2012/157940 · Cited by 54
Dysregulation of the NLRP3 Inflammasome in Diabetic Retinopathy and Potential Therapeutic Targets
Raman, K. S., & Matsubara, J. A. (2020) · Ocular Immunology and Inflammation · doi:10.1080/09273948.2020.1811350 · Cited by 52
Do Genomic Factors Play a Role in Diabetic Retinopathy?
Cabrera, A. P., Monickaraj, F., Rangasamy, S., Hobbs, S., McGuire, P. G., & Das, A. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9010216 · Cited by 74
Gene therapy for diabetic retinopathy: Are we ready to make the leap from bench to bedside?
Wang, J.-H., Ling, D. L., Tu, L., van Wijngaarden, P., Dusting, G. J., & Liu, G. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.01.003 · Cited by 52
Hirsch, J. D., Bounthavong, M., Arjmand, A., Ha, D. R., Cadiz, C. L., Zimmerman, A., Ourth, H. L., Morreale, A. P., Edelman, S. V., & Morello, C. M. (2017) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2017.23.3.318 · Cited by 52
Effects of lipid-lowering agents on diabetic retinopathy: a Meta-analysis and systematic review
Shi, R., Zhao, L. Q., Wang, F., Liu, F., Chen, Z., Li, R., Liu, Y., & Lin, R. (2018) · International Journal of Ophthalmology · doi:10.18240/ijo.2018.02.18 · Cited by 53
Liang, W., Huang, L., Whelchel, A. E., Yuan, T., Ma, X., Cheng, R., Takahashi, Y., Karamichos, D., & Ma, J. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2217576120 · Cited by 51
Zhong, X., Du, Y., Yuan, L., Liu, N., Guo, Y., & Pan, T. (2015) · Gene · doi:10.1016/j.gene.2015.04.045 · Cited by 52
Metadata
- Authors
- The ACCORD Study Group and ACCORD Eye Study Group
- Corresponding author
- The ACCORD Study Group and ACCORD Eye Study Group
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2010-07-15
- Volume
- 363
- Issue
- 3
- Pages
- 233-244
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4026164
- OpenAlex
- W2219384223
- Semantic Scholar
- 9a607a3bfd9432a917f703d573fdaa1052647711
- Cited by
- 1,311
- References
- 36
- Citations by year
- 2026: 54 · 2025: 60 · 2024: 66 · 2023: 86 · 2022: 73 · 2021: 94 · 2020: 96 · 2019: 57 · 2018: 78 · 2017: 87 · 2016: 82 · 2015: 84 · 2014: 74 · 2013: 81 · 2012: 93
- FWCI
- 111.95
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Abbott Laboratories
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Gilead Sciences
- Regeneron Pharmaceuticals
- Massachusetts Medical Society
- Omron Healthcare
- Bayer HealthCare
- Daiichi-Sankyo
- Novo Nordisk
- Servier
- National Institutes of Health (n01hc95183-23-0-0, n01hc95180-24-0-1, n01hc95184-24-0-1, n01hc95181-23-0-1, n01hc95182-23-0-1, Z99 EY999999, n01hc95178-28-0-1, n01hc95179-25-0-0)
- Centers for Disease Control and Prevention
- National Institute on Aging
- National Heart, Lung, and Blood Institute (N01- HC-95181, R01HL073030, N01 HC095184, N01-HC- 95180, N01-HC-95178, N01 HC095182, N01 HC095181, Y01 HC001010, N01-HC-095183, N01 HC095178, N01-HC-95184, N01HC95179, IAAY1-HC-1010, IAA #Y1-HC-9035, N01 HC095180, Y01 HC009035, N01‐HC‐95183, N01-HC-95182, N01 HC095179)
- National Eye Institute (ZIAEY000410)
- National Institute of Diabetes and Digestive and Kidney Diseases
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- diabetic retinopathy, retinopathy progression, type 2 diabetes, tight glycemic control, HbA1c, fenofibrate, simvastatin, dyslipidemia, blood pressure control, laser photocoagulation, vitrectomy, cardiovascular risk reduction, combination therapy, Early Treatment Diabetic Retinopathy Study
- MeSH terms
- Antihypertensive Agents, Hypolipidemic Agents, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Diabetic Retinopathy, Drug Therapy, Combination, Female, Follow-Up Studies, Glycated Hemoglobin, Humans, Hyperglycemia, Hypertension, Hypoglycemic Agents, Cholesterol, LDL, Male, Middle Aged, Fenofibrate, Disease Progression, Simvastatin, Dyslipidemias
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
